Celltrion's Steqeyma completes rollout in major European markets, intensifying competition in the ustekinumab market. FDA approved Steqeyma in December 2024 for inflammatory conditions ...

Switching from ustekinumab to biosimilar SB17 maintains long-term efficacy and safety in psoriasis patients, supporting cost-effective treatment options. A phase 3 trial with 503 participants ...

In this article, we are going to take a look at where Uniti Group Inc. (NASDAQ:UNIT) stands against the other data stocks. We believe data centers are currently experiencing a remarkable growth ...

Uniti Group Inc stock price live, this page displays NASDAQ UNIT stock exchange data. View the UNIT premarket stock price ahead of the market session or assess the after hours quote. Monitor the ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term comparable efficacy and safety up to week 52. Patients with psoriasis who switched ...

J&J has said it will now need upfront payment in full for its anticoagulant Xarelto (rivaroxaban) and immunology therapy Stelara (ustekinumab), with a rebate paid later, rather than the previous ...

After hours: January 28 at 4:01:49 PM EST Loading Chart for UNTY ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...